Intra-Cellular Therapies Inc. buy Cantor Fitzgerald
Start price
24.04.24
/
50%
€68.50
Target price
24.04.25
€112.30
Performance (%)
-11.68%
Price
10.05.24
€60.50
Summary
This prediction is currently active. The price of Intra-Cellular Therapies Inc. has decreased since the start of the prediction. Compared to the start price this results in a performance of -11.68%. This prediction currently runs until 24.04.25. The prediction end date can be changed by Cantor_Fitzgerald at any time. Cantor_Fitzgerald has 50% into this predictionPerformance without dividends (%)
Name | 1w |
---|---|
Intra-Cellular Therapies Inc. | -5.469% |
iShares Core DAX® | 4.094% |
iShares Nasdaq 100 | 1.424% |
iShares Nikkei 225® | -1.572% |
iShares S&P 500 | 1.822% |
Comments by Cantor_Fitzgerald for this prediction
In the thread Intra-Cellular Therapies Inc. diskutieren
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $120.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat
Stopped prediction by Cantor_Fitzgerald for Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc.
Start price
Target price
Perf. (%)
€64.80
23.02.24
23.02.24
€93.28
23.02.25
23.02.25
-6.64%
10.05.24
10.05.24
Intra-Cellular Therapies Inc.
Start price
Target price
Perf. (%)
€59.40
14.12.23
14.12.23
€91.89
14.12.24
14.12.24
1.85%
10.05.24
10.05.24
Intra-Cellular Therapies Inc.
Start price
Target price
Perf. (%)
€51.30
03.11.23
03.11.23
€94.07
03.11.24
03.11.24
17.93%
10.05.24
10.05.24
Intra-Cellular Therapies Inc.
Start price
Target price
Perf. (%)
€52.40
29.03.23
29.03.23
€80.23
29.03.24
29.03.24
22.14%
30.03.24
30.03.24